Joseph Zakrzewski - Onxeo SA Non-Executive Chairman of the Board
| C4X Stock | EUR 0.08 0 3.34% |
Chairman
Mr. Joseph S. Zakrzewski was appointed NonExecutive Chairman of the Board of Directors of Onxeo SA, effective as of the end of January 2016. He has more than 25 years of experience in the healthcare industry. His career started with Eli Lilly Company in the USA. He joined as process engineer with responsibility for biologics development and manufacturing, became Senior Financial Analyst and Head of Manufacturing and Development, then Manager and Director of Corporationrationrate Business Development, before being appointed VP Global Corporationrationrate Business Development . He was Chief Operating Officer of Reliant Pharmaceuticals, and then joined the biotechnology company Xcellerex as CEO . From 2010 to 2013, he was Chairman and CEO of Amarin Corporation, where he remains a director. He has also been a venture partner at Orbimed Advisors, one of the leading VC funds dedicated to the healthcare industry . Joseph Zakrzewski is a board member with several biotechnology companies in Europe and in the USA, public and private, including Insulet Corporationrationration, Amarin Corporationrationration, Thrasos Therapeutics, Acceleron Pharma, Gliacure Inc., and SiteOne Therapeutics. He received a BS in Chemical Engineering and a MS degree in Biochemical Engineering from Drexel University. He has an MBA in Finance from the University of Indiana. since 2016.
| Age | 56 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 33 1 45 58 76 00 |
| Web | https://www.onxeo.com |
Joseph Zakrzewski Latest Insider Activity
Tracking and analyzing the buying and selling activities of Joseph Zakrzewski against Onxeo SA stock is an integral part of due diligence when investing in Onxeo SA. Joseph Zakrzewski insider activity provides valuable insight into whether Onxeo SA is net buyers or sellers over its current business cycle. Note, Onxeo SA insiders must abide by specific rules, including filing SEC forms every time they buy or sell Onxeo SA'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Joseph Zakrzewski over six months ago Acquisition by Joseph Zakrzewski of 23742 shares of AN2 Therapeutics at 5.91 subject to Rule 16b-3 | ||
Joseph Zakrzewski over six months ago Exercise or conversion by Joseph Zakrzewski of 14150 shares of Cyteir Therapeutics subject to Rule 16b-3 | ||
Joseph Zakrzewski over six months ago Sale by Joseph Zakrzewski of 100000 shares of AN2 Therapeutics | ||
Joseph Zakrzewski over a year ago Purchase by Joseph Zakrzewski of 1000 shares of Cyteir Therapeutics |
Onxeo SA Management Efficiency
The company has return on total asset (ROA) of (0.1108) % which means that it has lost $0.1108 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3966) %, meaning that it generated substantial loss on money invested by shareholders. Onxeo SA's management efficiency ratios could be used to measure how well Onxeo SA manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 |
Onxeo SA Leadership Team
Elected by the shareholders, the Onxeo SA's board of directors comprises two types of representatives: Onxeo SA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Onxeo. The board's role is to monitor Onxeo SA's management team and ensure that shareholders' interests are well served. Onxeo SA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Onxeo SA's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elisabeth Carstensen, Director of Alliance Management, Member of the Executive Committee | ||
| Russell Greig, Independent Member of the Board | ||
| Remi Droller, Member of the Board - Representative of Kurma Life Science Partners | ||
| Daniele GuyotCaparros, Independent Member of the Board | ||
| Michel Forest, Vice President Quality Qualified Person and Member of the Executive Committee | ||
| Caroline Lemarchand, Preclinical R&D Director, Member of the Executive Committee | ||
| Olivier Beaumont, Chief Medical Officer, Member of the Executive Committee | ||
| Aude Michel, Director of Legal Affairs, Agreements and Licensing, Member of the Executive Committee | ||
| Huiping Jiang, VP Assurance | ||
| Sonia Vallons, Quality Assurance Director, Member of the Executive Committee | ||
| Thomas Hofstaetter, Independent Member of the Board | ||
| MD MPH, CEO Pres | ||
| Delphine Lucas, Regulatory Affairs Director, Member of the Executive Committee | ||
| Francoise Bono, Chief Scientific Officer, Member of the Executive Committee | ||
| Nicolas Trebouta, Member of the Board - Permanent Representative of Financiere de la Montagne | ||
| Audrey LegentilDumery, Director of Human Resources, Member of the Executive Committee | ||
| Judith Greciet, Chief Executive Officer, Member of the Executive Committee, Member of the Board | ||
| Nicolas Fellman, Vice President, Chief Financial Officer, Member of the Executive Committee | ||
| David Solomon, Independent Member of the Board | ||
| Joseph Zakrzewski, Non-Executive Chairman of the Board | ||
| Louis Kayitalire, Vice President Head of Research & Development | ||
| Philippe Maitre, Executive Vice President and Chief of U.S. Operations | ||
| Nicolas Fellmann, CFO Director |
Onxeo Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Onxeo SA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (2.88) % | |||
| Current Valuation | 5.34 M | |||
| Shares Outstanding | 111.06 M | |||
| Shares Owned By Insiders | 13.25 % | |||
| Shares Owned By Institutions | 12.72 % | |||
| Price To Earning | 50.90 X | |||
| Price To Book | 0.48 X | |||
| Price To Sales | 5.35 X |
Currently Active Assets on Macroaxis
Other Information on Investing in Onxeo Stock
Onxeo SA financial ratios help investors to determine whether Onxeo Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Onxeo with respect to the benefits of owning Onxeo SA security.